Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Endocyte Inc.

Division of Novartis AG
www.endocyte.com

Latest From Endocyte Inc.

Novartis' New Oncology CEO Schaffert Has A Potential Blockbuster Launch On Her Hands

In an interview at Novartis' research campus in Cambridge, Mass., Schaffert spoke about the upcoming launch of Piqray for breast cancer, building in radiopharmaceuticals, Kymriah's ongoing manufacturing challenges and more.

Cancer Business Strategies

Novartis Delighted With Xiidra Deal Despite Eye-Watering Price

Shire got hold of the eyedrop product in 2013 through its acquisition of SARcode which cost $160m and despite struggling on the market, Novartis is paying $3.4bn upfront to buy Xiidra.

M & A Companies

2018 Saw Record Launches, But No Big Splash

The number of US drug approvals in 2018 was striking, but most of the novel products launched last year are for rare diseases or niche cancers, meaning commercial success may be in the eye of the beholder.

Launches Growth

Novartis R&D Chief Tsai On 2019 Goals, Priorities, BD And Digital Advances

R&D head John Tsai spoke with Scrip about culture change at Novartis as it moves toward advanced therapy platforms and embraces digital technologies, and offered a peek into what’s in store for R&D in 2019 and beyond.

Leadership Companies
See All

Company Information

  • Industry
  • Biotechnology
    • Pharmacogenetics-Pharmacogenomics
  • In Vitro Diagnostics
  • Medical Devices
    • Diagnostic Imaging Equipment & Supplies
  • Pharmaceuticals
    • Drug Delivery
    • Radiopharmaceuticals, Contrast Agents
  • Therapeutic Areas
  • Cancer
  • Inflammation
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Novartis AG
  • Senior Management
  • Michael A Sherman, Pres. & CEO
    Michael T Andriole, CFO
    Matthew Call, VP, Bus. Dev. & Mktg.
    Philip S Low, PhD, CSO
    Alison A Armour, MD, CMO
  • Contact Info
  • Endocyte Inc.
    Phone: (765) 463-7175
    3000 Kent Ave.
    Ste. A1-100
    West Lafayette, IN 47906
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register